Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, has announced its participation in TD Cowen's 45th Annual Health Care Conference. The company's management will deliver a presentation on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA.
Interested parties can access a live webcast of the presentation through PacBio's investors page at investor.pacificbiosciences.com. The webcast recording will remain available for viewing for a minimum of 30 days after the event.
PacBio (NASDAQ: PACB) announced the grant of equity incentives to a new employee, consisting of a non-qualified stock option for 400,000 shares and restricted stock units (RSUs) for 300,000 shares under the 2020 Inducement Plan. The stock option has an exercise price of $1.33 per share, matching PacBio's closing price on February 10, 2025.
The option shares will vest over four years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments of 25% each. Both grants are subject to the employee's continued service through applicable vesting dates and were awarded as inducement for employment in compliance with Nasdaq Marketplace Rule 5635(c)(4).
PacBio (PACB) reported Q4 2024 financial results with revenue of $39.2 million, marking a 33% decrease from $58.4 million in the prior year. The quarter saw instrument revenue of $15.3 million, including 23 Revio® and 7 Vega™ systems, while consumables revenue remained flat at $18.8 million.
The company reported a GAAP net income of $3.6 million ($0.01 per share), compared to a loss of $82.0 million in Q4 2023, primarily due to a $154.4 million gain from debt restructuring. Non-GAAP net loss was $55.3 million. Cash position stood at $389.9 million, down from $631.4 million year-over-year.
Notable developments included the early launch of the Vega sequencing platform, implementation of SPRQ chemistry enabling sub-$500 genome sequencing, and a debt restructuring that reduced convertible notes by $259 million.
PacBio (NASDAQ: PACB) has appointed David Ruggiero as the new Global Head of Sales & Service, effective February 10, 2025. Ruggiero brings over 20 years of sales leadership experience in technology and life sciences sectors. His previous roles include Senior Vice President, North America at Sinch AB, and senior positions at Zoom Video Communications, Microsoft , and Thermo Fisher Scientific, where he served as Chief Commercial Officer for the Life Sciences Solutions Group.
In his new role, Ruggiero will lead PacBio's global sales and service operations, focusing on accelerating the adoption of the company's sequencing platforms and enhancing worldwide customer support. The appointment aligns with PacBio's strategy to expand its global presence and deliver innovative sequencing solutions to customers.
PacBio (PACB) has scheduled its fourth quarter 2024 financial results conference call for Thursday, February 13, 2025, at 4:30 pm Eastern Time (1:30 pm Pacific Time). Investors and interested parties can access the webcast through PacBio's investor relations website. For those preferring to dial in, toll-free and international numbers are available, and participants are advised to join ten minutes before the start time.
PacBio (NASDAQ: PACB) announced the appointment of Chris Smith to its Board of Directors, effective immediately. Smith, currently CEO of NeoGenomics (NASDAQ:NEO), brings extensive experience in life sciences and healthcare industries. He previously served as Chairman and CEO of Ortho Clinical Diagnostics and CEO of Cochlear
The appointment aims to leverage Smith's expertise in diagnostics and laboratory testing markets as PacBio continues its expansion into clinical genomics. Concurrent with Smith's appointment, David Meline, who has served on the Board since 2023, is stepping down from his position.
Christian Henry, PacBio's President and CEO, highlighted Smith's deep expertise in clinical diagnostics and genomics, along with his experience in scaling high-growth companies, as valuable assets for PacBio's future growth in the clinical genomics market.
PacBio (NASDAQ: PACB) announced its key role in a groundbreaking study published in Nature Genetics that successfully resolved a complex rare Mendelian condition using their advanced sequencing technology. The research, conducted in collaboration with the University of Washington and the Undiagnosed Diseases Network, utilized PacBio's Revio™ sequencing system to analyze a 9-month-old patient with bilateral retinoblastomas and developmental delays.
The study employed PacBio's synchronized Fiber-seq and Kinnex multiomic approach, which uniquely integrated long-read genomic, transcriptomic, methylomic, and epigenomic data in a single analysis. This comprehensive approach identified a chromosome X;13 balanced translocation affecting four key genes, each through different molecular mechanisms - a discovery that previous diagnostic methods, including short-read sequencing, failed to detect.
PacBio (NASDAQ: PACB) has announced that the Global Institute for Food Security (GIFS) at the University of Saskatchewan has become Canada's first Revio PacBio Certified Service Provider (CSP). GIFS will offer PacBio's HiFi sequencing technology through its Omics and Precision Analytics Laboratory (OPAL) platform.
The certification ensures that GIFS has demonstrated the necessary capability, expertise, and infrastructure to deliver high-quality PacBio sequencing solutions, including genome assemblies, transcriptomics, and epigenetics. GIFS' OPAL platform provides comprehensive genomics solutions with automation, bioinformatics, and advanced data analysis capabilities.
This partnership aims to provide Canadian researchers and global clients access to highly accurate long-read sequencing data for various applications, from agricultural innovation to disease discovery.
PacBio (NASDAQ: PACB) and Radboud University Medical Center announced significant results from a study published in the American Journal of Human Genetics, demonstrating the effectiveness of PacBio's HiFi long-read sequencing technology in rare disease diagnostics. The study analyzed 100 challenging patient samples, achieving a 93% identification rate of pathogenic variants previously difficult to detect using short-read methods.
Key operational metrics include nearly 1,000 samples processed as of January 10, 2025, with 862 fully analyzed since August 2024. The collaboration has implemented automated library preparation for 24 samples per run, with plans to scale to 96 samples. Radboudumc has expanded its Revio instrument fleet to support 5,000 genomes using SPRQ chemistry, with first-tier diagnostic rollout targeted for summer 2025.
PacBio (NASDAQ: PACB) reported preliminary Q4 2024 revenue of $39.2 million and full-year 2024 revenue of $154.0 million, representing year-over-year declines of 33% and 23% respectively. The company shipped 23 Revio and 7 Vega sequencing systems in Q4, with instrument revenue at $15.3 million, down from $35.1 million in Q4 2023.
Notable developments include the early launch of the Vega benchtop system and SPRQ chemistry introduction, enabling sub-$500 HiFi genome sequencing on the Revio system. Consumables revenue remained stable at $18.8 million, with Revio achieving approximately $240,000 in annualized pull-through. The company strengthened its balance sheet by restructuring $459 million in convertible notes and ended 2024 with approximately $390 million in cash and investments.